krn330
Colorectal Cancer
Kyowa Kirin Co., Ltd.monoclonal_antibodyPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 59/ 100
Competitive context
840 Active assets in the Colorectal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Desflurane Peter MacCallum Cancer Centre, Australia | Phase 4 | BBB |
MARBLE DUST James Varani | Phase 2/3 | BB |
Orectalip Sinphar Pharmaceutical Co., Ltd | Phase 4 | BB |
Eloxatin Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 4 | BB |
FLUOROURACILUM UNICANCER | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →